Financial Data and Key Metrics Changes - The company reported a revenue of $32 million for Q3 2023, an increase from $29 million in Q2 2023, primarily driven by collaboration with Gilead [65] - Cash at the end of September 30, 2023, was $950 million, with net cash utilization of $188 million through three quarters of 2023 [40][41] - The expected cash utilization for the full year 2023 is between $265 million and $290 million, down from previous guidance of $295 million to $325 million [40] Business Line Data and Key Metrics Changes - The company continues to execute on its pipeline, including the HIF-2-alpha and adenosine pathway programs, with upcoming data readouts expected for AB521 and QEMLI [24][26] - The EDGE-Gastric study showed a confirmed overall response rate of 59% in the overall population, with a six-month landmark progression-free survival (PFS) of 77% [12][16] Market Data and Key Metrics Changes - The market opportunity for gastric, gastroesophageal junction, and esophageal adenocarcinomas is estimated to exceed $3 billion, with approximately 25,000 patients in the U.S. alone [15] - The company is positioned to be first to market with an anti-TIGIT antibody in the first-line treatment of upper GI adenocarcinomas, which is one of the fastest-growing cancer types in the U.S. and Western Europe [15][43] Company Strategy and Development Direction - The company aims to secure its position as first-to-market and best-in-class in the anti-TIGIT space, with a focus on innovative combination therapies [57] - The ongoing Phase 3 study, STAR-221, is designed to support regulatory requirements and is enrolling well ahead of schedule, driven by enthusiasm in the TIGIT field [91] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the data supporting DOM as a potential best-in-class anti-TIGIT therapy, highlighting the differentiated safety and efficacy profile compared to competitors [43][56] - The company anticipates that the data from the EDGE-Gastric study will enhance interest and accelerate recruitment in the STAR-221 study [25][91] Other Important Information - The company has a rigorous synthetic-controlled dataset for gemobraxain, showing meaningful differentiation from combination therapy [26] - The company plans to share comprehensive data from the ARC-8 study early next year, including overall survival metrics [38] Q&A Session Summary Question: Can you comment on the design for STAR-221 regarding TAP high and low populations? - Management indicated that the trial is designed to analyze both populations, but specific details on statistical analysis plans were not disclosed [44] Question: What data will indicate additional efficacy for HIF-2-alpha? - Management suggested that the Phase 2 data in the expansion cohort will provide insights into the efficacy of AB521 compared to existing treatments [48] Question: How does the company view the competitive landscape for anti-TIGIT therapies? - Management noted a growing enthusiasm for anti-TIGIT therapies among oncology KOLs, with expectations for FDA approvals [56] Question: How does the company plan to differentiate AB521 from Merck's Belzutepin? - Management emphasized that AB521 has better pharmacokinetic properties, allowing for higher drug exposure without the limitations seen in Belzutepin [72][59] Question: What are the expectations for the upcoming data from the ARC-8 study? - Management expects to present mature overall survival data early next year, which will provide a substantial dataset for analysis [62]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _____________________________________ FORM 10-Q _____________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________to _______________ Commission File Number: 001-38419 ______________ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________to _______________ Commission File Number: 001-38419 Arcus Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47-3898 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38419 Arcus Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or organization) 3928 Point Eden ...

Part I [Business](index=7&type=section&id=Item%201.%20Business) Arcus Biosciences is a clinical-stage biopharmaceutical company focused on immuno-oncology, with its lead anti-TIGIT antibody in four Phase 3 studies and strong reliance on strategic collaborations - The company is a clinical-stage biopharmaceutical firm focused on creating best-in-class therapies, with its most advanced molecule, an anti-TIGIT antibody, in **four Phase 3 registrational studies** for lung and gastrointestinal cancers[26](index=26&type=chunk) - Arcus has **five clinical programs** targeting TIGIT, PD-1, adenosine receptors (A2a/A2b), CD73, and HIF-2α, with three antibodies and three small molecules being evaluated across **13 clinical studies**[29](index=29&type=chunk) - The company's strategy focuses on building a differentiated portfolio of intra-portfolio combinations, designing efficient clinical trials, pursuing indications with strong biological rationales, and maximizing value through strategic collaborations like those with Gilead and Taiho[64](index=64&type=chunk) - As of December 31, 2022, the company had just over **500 full-time employees**, with approximately **80% engaged in research and development activities**[161](index=161&type=chunk) [Company Overview and Clinical Pipeline](index=7&type=section&id=Company%20Overview%20and%20Clinical%20Pipeline) Arcus Biosciences is advancing a diverse immuno-oncology clinical pipeline, centered on the anti-TIGIT antibody domvanalimab in four Phase 3 trials Key Clinical Programs and Status | Molecule | Target | Key Trials | Status | | :--- | :--- | :--- | :--- | | **Domvanalimab (dom)** | anti-TIGIT | ARC-10, STAR-121, STAR-221, PACIFIC-8 | 4 Phase 3 studies ongoing | | **Zimberelimab (zim)** | anti-PD-1 | Cornerstone in multiple combination trials | Approved in China for Hodgkin's Lymphoma | | **Etrumadenant (etruma)** | Adenosine A2a/A2b Receptor | ARC-6, ARC-7, ARC-9 | Phase 2 studies ongoing | | **Quemliclustat (quemli)** | CD73 | ARC-8, EDGE-Lung | Phase 1/1b and Phase 2 studies ongoing | | **AB521** | HIF-2α | ARC-20 | Phase 1 study ongoing | - The ARC-7 Phase 2 study of domvanalimab plus zimberelimab showed a **45% reduction in risk of disease progression or death** and a median PFS of **12.0 months**, compared to **5.4 months** for zimberelimab monotherapy in 1L NSCLC (PD-L1≥50%)[35](index=35&type=chunk) - Early-stage programs include AB598 (anti-CD39 antibody) and AB801 (Axl inhibitor), with plans to advance a small molecule for inflammation into preclinical development in 2023[28](index=28&type=chunk)[48](index=48&type=chunk) [License and Collaborations](index=12&type=section&id=License%20and%20Collaborations) Arcus's business model heavily relies on strategic partnerships, notably with Gilead for co-development and funding, and Taiho for Asian markets, alongside in-licensed core assets - Gilead has an exclusive license to zimberelimab and has exercised options for the anti-TIGIT, adenosine receptor antagonist, and CD73 programs; for optioned programs, Arcus and Gilead co-develop and share global costs, with Arcus retaining U.S. co-promotion rights[29](index=29&type=chunk)[52](index=52&type=chunk)[53](index=53&type=chunk) - Gilead has the right to purchase up to **35% of Arcus's outstanding common stock** until July 2025; as of year-end 2022, Gilead owned approximately **18.9%** and has two designees on Arcus's Board of Directors[55](index=55&type=chunk)[56](index=56&type=chunk)[467](index=467&type=chunk) - Taiho has licensed rights for Japan and other Asian territories for the etrumadenant, zimberelimab, and anti-TIGIT programs, with potential milestone payments up to **$275 million per program** plus royalties[57](index=57&type=chunk)[58](index=58&type=chunk) - Arcus in-licensed zimberelimab from WuXi Biologics and domvanalimab from Abmuno Therapeutics, with future milestone and royalty obligations to both[59](index=59&type=chunk)[61](index=61&type=chunk) [Competition](index=15&type=section&id=Competition) The company faces intense competition in immuno-oncology from large pharmaceutical and biotech firms across its key drug programs - The company faces substantial competition from large pharmaceutical and biotech companies like AstraZeneca, Beigene, Bristol-Myers Squibb, Merck, and Roche/Genentech[68](index=68&type=chunk)[69](index=69&type=chunk) Key Competitors by Drug Program | Arcus Program | Competitors in Development | | :--- | :--- | | **Anti-TIGIT** | Beigene, Roche/Genentech, Merck | | **Adenosine Receptor Antagonist** | Incyte, Merck KGaA, AstraZeneca, iTeos, Novartis | | **CD73 Inhibitor** | AstraZeneca, Bristol-Myers Squibb, Corvus, Novartis | | **Anti-PD-1** | Multiple companies with approved products (Merck, BMS, etc.) | | **HIF-2α Inhibitor** | Merck (approved product), Novartis, NiKang Therapeutics | [Intellectual Property](index=16&type=section&id=Intellectual%20Property) Arcus's commercial success relies on its patent portfolio, which as of February 2023, includes 7 issued U.S. patents and 426 foreign applications, expiring between 2035 and 2042 - As of February 1, 2023, the company's patent portfolio includes **7 issued U.S. patents**, **38 pending or issued U.S. patent applications**, and approximately **426 pending or issued foreign patent applications**[79](index=79&type=chunk) - Issued patents and any future patents from pending applications are projected to expire between **2035 and 2042**, excluding any potential patent term adjustments or extensions[79](index=79&type=chunk) [Government Regulation](index=17&type=section&id=Government%20Regulation) The company's operations are extensively regulated by the FDA, covering drug development, approval, and post-market requirements, alongside various U.S. healthcare laws and recent reforms like the IRA - The company is subject to extensive regulation by the FDA, requiring a rigorous process of preclinical testing and clinical trials (Phase 1, 2, 3) before a drug or biologic can be marketed[83](index=83&type=chunk)[84](index=84&type=chunk)[85](index=85&type=chunk) - The FDA offers expedited programs such as Fast Track, priority review, accelerated approval, and Breakthrough Therapy designation to simplify or speed up the review process for drugs treating serious conditions[100](index=100&type=chunk)[101](index=101&type=chunk)[102](index=102&type=chunk) - The company is subject to various U.S. healthcare laws, including the federal Anti-Kickback Statute, False Claims Act (FCA), and HIPAA, which regulate interactions with healthcare providers and protect patient data[126](index=126&type=chunk)[127](index=127&type=chunk)[129](index=129&type=chunk) - Recent healthcare reform, such as the Inflation Reduction Act of 2022 (IRA), is expected to impact the business by allowing Medicare to negotiate drug prices and imposing rebates for price increases that outpace inflation[147](index=147&type=chunk)[150](index=150&type=chunk)[307](index=307&type=chunk) [Risk Factors](index=36&type=section&id=Item%201A.%20Risk%20Factors) The company faces significant risks including operating losses, high drug development failure rates, heavy reliance on Gilead, intense competition, intellectual property challenges, and complex regulatory environments - The company has a history of operating losses, with a net loss of **$267 million** in 2022 and an accumulated deficit of **$542 million** as of December 31, 2022; it anticipates continued significant losses[169](index=169&type=chunk) - A key risk is the heavy dependence on the collaboration with Gilead for research, development, and commercialization; conflicts, termination of the agreement, or Gilead choosing not to exercise options could adversely affect the business[207](index=207&type=chunk)[210](index=210&type=chunk) - The company relies on single-source third-party manufacturers, including WuXi Biologics in China for zimberelimab, which increases supply chain risk and exposure to import/export restrictions[214](index=214&type=chunk) - The company faces potential patent litigation risks, noting specific patents from Bristol-Myers Squibb (anti-PD-1) and Genentech (anti-PD-1/anti-TIGIT combo) that could impact commercialization of zimberelimab and domvanalimab[248](index=248&type=chunk) - The business is highly dependent on its founders, CEO Terry Rosen, Ph.D., and President Juan Jaen, Ph.D., whose departure would be difficult to replace[267](index=267&type=chunk)[268](index=268&type=chunk) [Unresolved Staff Comments](index=71&type=section&id=Item%201B.%20Unresolved%20Staff%20Comments) The company reports no unresolved staff comments from the SEC - None[331](index=331&type=chunk) [Properties](index=71&type=section&id=Item%202.%20Properties) As of December 31, 2022, Arcus leases approximately 151,000 sq ft in Hayward and 109,000 sq ft in Brisbane for its operations, with leases expiring in 2031 - The company leases approximately **151,000 sq. ft.** in Hayward, CA for its headquarters and **109,000 sq. ft.** in Brisbane, CA; both leases expire in 2031[332](index=332&type=chunk) [Legal Proceedings](index=71&type=section&id=Item%203.%20Legal%20Proceedings) The company is not currently a party to any material legal proceedings - The company is not currently a party to any material legal proceedings[333](index=333&type=chunk) [Mine Safety Disclosures](index=71&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - None[334](index=334&type=chunk) Part II [Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](index=72&type=section&id=Item%205.%20Market%20for%20Registrant%27s%20Common%20Equity%2C%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities) Arcus Biosciences' common stock trades on the NYSE under "RCUS", with no history or plans for cash dividends, retaining earnings for business development - The company's common stock trades on the NYSE under the symbol **"RCUS"**[337](index=337&type=chunk) - Arcus has never paid cash dividends and does not intend to in the foreseeable future[338](index=338&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=74&type=section&id=Item%207.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) In 2022, Arcus reported **$112 million** in revenue, a net loss of **$267 million**, and ended the year with **$1.14 billion** in cash, sufficient to fund operations into 2026 [Results of Operations](index=78&type=section&id=Results%20of%20Operations) In 2022, total revenues decreased **71%** to **$112 million**, while R&D and G&A expenses increased, resulting in a net loss of **$267 million** Results of Operations (in millions) | | 2022 | 2021 | Change | | :--- | :--- | :--- | :--- | | **Total revenues** | $112 | $383 | (71)% | | **Research and development** | $288 | $257 | 12% | | **General and administrative** | $104 | $72 | 44% | | **Total operating expenses** | $392 | $329 | 19% | | **Net income (loss)** | $(267) | $53 | * | - The decrease in 2022 revenue was primarily due to higher revenues recognized in 2021 from Gilead's exercise of its options on several programs[368](index=368&type=chunk) - The **12% increase in R&D expenses** in 2022 was driven by **$167 million** in higher costs for expanded clinical activities, offset by **$136 million** in higher cost-sharing reimbursements from Gilead[370](index=370&type=chunk) - The **44% increase in G&A expenses** in 2022 was primarily due to a **$15 million increase** in employee compensation costs and a **$13 million increase** in office facilities expense to support higher headcount[374](index=374&type=chunk) [Liquidity and Capital Resources](index=79&type=section&id=Liquidity%20and%20Capital%20Resources) As of December 31, 2022, Arcus held **$1.14 billion** in cash, sufficient to fund operations into 2026, largely due to a **$725 million** payment from Gilead - As of December 31, 2022, the company had **$1.14 billion** in cash, cash equivalents, and marketable securities[380](index=380&type=chunk) - Management believes existing cash will be sufficient to fund planned operations into **2026**[382](index=382&type=chunk) Cash Flow Summary (in millions) | | 2022 | 2021 | | :--- | :--- | :--- | | **Net cash from operating activities** | $438 | $(256) | | **Net cash used in investing activities** | $(413) | $(4) | | **Net cash from financing activities** | $33 | $237 | - The positive operating cash flow in 2022 was primarily due to the receipt of **$725 million** from Gilead in January 2022 related to their option exercises[386](index=386&type=chunk) [Critical Accounting Judgments and Estimates](index=81&type=section&id=Critical%20Accounting%20Judgments%20and%20Estimates) Critical accounting judgments primarily involve revenue recognition from collaboration agreements, requiring significant estimates for performance obligations and development timelines - Revenue recognition requires significant judgment, especially in allocating transaction prices to performance obligations and estimating standalone selling prices using forecasts, discount rates, and success probabilities[400](index=400&type=chunk)[401](index=401&type=chunk) - For revenue recognized over time, estimates of the total effort required to satisfy performance obligations are critical; a hypothetical **10% change** in this estimate for Gilead-related R&D activities would have impacted 2022 revenue by up to **$7 million**[402](index=402&type=chunk) - For the domvanalimab license transferred to Gilead in 2021, a **10% change** in the estimated cash flows used in the discounted cash flow valuation would have changed the revenue recognized in 2021 by approximately **$20 million**[404](index=404&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=83&type=section&id=Item%207A.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company faces market risks from interest rate fluctuations on its **$1.14 billion** portfolio and foreign currency exchange rates, neither of which is expected to have a material impact - The company has interest rate risk related to its **$1.14 billion** in cash, cash equivalents, and marketable securities; a **100 basis point change** in interest rates is not expected to have a material effect[407](index=407&type=chunk) - The company is exposed to foreign currency exchange risk from contracts with non-U.S. entities, but a **20% adverse change** in exchange rates is not expected to materially impact its financial position[408](index=408&type=chunk) [Financial Statements and Supplementary Data](index=84&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data) This section presents the company's audited consolidated financial statements for 2020-2022, with an unqualified auditor's opinion from Ernst & Young LLP, highlighting the Gilead collaboration as a critical audit matter Consolidated Balance Sheet Data (in millions) | | Dec 31, 2022 | Dec 31, 2021 | | :--- | :--- | :--- | | **Current Assets** | $1,067 | $1,262 | | Cash and cash equivalents | $206 | $148 | | Marketable securities | $803 | $351 | | **Total Assets** | $1,345 | $1,592 | | **Current Liabilities** | $193 | $166 | | Deferred revenue, noncurrent | $355 | $462 | | **Total Liabilities** | $688 | $750 | | **Total Stockholders' Equity** | $657 | $842 | Consolidated Statement of Operations Data (in millions) | | 2022 | 2021 | 2020 | | :--- | :--- | :--- | :--- | | **Total revenues** | $112 | $383 | $78 | | **Research and development** | $288 | $257 | $159 | | **General and administrative** | $104 | $72 | $43 | | **Net income (loss)** | $(267) | $53 | $(123) | | **Net income (loss) per share, diluted** | $(3.71) | $0.71 | $(2.24) | [Changes in and Disagreements With Accountants on Accounting and Financial Disclosure](index=114&type=section&id=Item%209.%20Changes%20in%20and%20Disagreements%20With%20Accountants%20on%20Accounting%20and%20Financial%20Disclosure) The company reports no changes in or disagreements with its accountants on accounting and financial disclosure - None[575](index=575&type=chunk) [Controls and Procedures](index=114&type=section&id=Item%209A.%20Controls%20and%20Procedures) Management concluded that disclosure controls and internal control over financial reporting were effective as of December 31, 2022, with an unqualified auditor's opinion - Management concluded that the company's disclosure controls and procedures were effective as of December 31, 2022[578](index=578&type=chunk) - Management concluded that the company's internal control over financial reporting was effective as of December 31, 2022, based on the COSO framework[582](index=582&type=chunk) - The independent registered public accounting firm, Ernst & Young LLP, issued an unqualified opinion on the effectiveness of the company's internal control over financial reporting as of December 31, 2022[583](index=583&type=chunk)[588](index=588&type=chunk) [Other Information](index=117&type=section&id=Item%209B.%20Other%20Information) The company reports no other information for this item - None[595](index=595&type=chunk) Part III [Directors, Executive Officers and Corporate Governance](index=118&type=section&id=Item%2010.%20Directors%2C%20Executive%20Officers%20and%20Corporate%20Governance) Information on directors, executive officers, and corporate governance is incorporated by reference from the upcoming 2023 Proxy Statement [Executive Compensation](index=118&type=section&id=Item%2011.%20Executive%20Compensation) Information regarding executive and director compensation is incorporated by reference from the company's upcoming Proxy Statement [Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters](index=118&type=section&id=Item%2012.%20Security%20Ownership%20of%20Certain%20Beneficial%20Owners%20and%20Management%20and%20Related%20Stockholder%20Matters) Information on security ownership and equity compensation plans is incorporated by reference from the company's upcoming Proxy Statement [Certain Relationships and Related Transactions, and Director Independence](index=118&type=section&id=Item%2013.%20Certain%20Relationships%20and%20Related%20Transactions%2C%20and%20Director%20Independence) Information regarding related person transactions and director independence is incorporated by reference from the company's upcoming Proxy Statement [Principal Accounting Fees and Services](index=118&type=section&id=Item%2014.%20Principal%20Accounting%20Fees%20and%20Services) Information regarding principal accounting fees and services is incorporated by reference from the company's upcoming Proxy Statement Part IV [Exhibits and Financial Statement Schedules](index=119&type=section&id=Item%2015.%20Exhibits%20and%20Financial%20Statement%20Schedules) This section lists documents filed as part of the Annual Report on Form 10-K, including financial statements and an index of all exhibits [Form 10-K Summary](index=119&type=section&id=Item%2016.%20Form%2010-K%20Summary) The company provides no summary for this item - None[605](index=605&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________to _______________ Commission File Number: 001-38419 Arcus Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47 ...

COMBINING TO CURE Arcus is at the forefront of designing precision combinations in the pursuit of cures for patients living with cancer. CORPORATE PRESENTATION September 2022 Forward-looking Statements/Safe Harbor This presentation contains forward-looking statements about Arcus Biosciences, Inc. ("we," "Arcus" or the "Company") made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements regarding events or results to occur in the future contained in t ...

COMBINING TO CURE Arcus is at the forefront of designing precision combinations in the pursuit of cures for patients living with cancer. 2Q22 CORPORATE PRESENTATION AUGUST 3, 2022 Forward-looking Statements/Safe Harbor This presentation contains forward-looking statements about Arcus Biosciences, Inc. ("we," "Arcus" or the "Company") made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements regarding events or results to occur in the future contained ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________to _______________ Commission File Number: 001-38419 Arcus Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47-3898 ...

COMBINING TO CURE Arcus is at the forefront of designing precision combinations in the pursuit of cures for patients living with cancer. 1Q22 Corporate Presentation May 9, 2022 Forward-looking Statements/Safe Harbor This presentation contains forward-looking statements about Arcus Biosciences, Inc. ("we," "Arcus" or the "Company") made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements regarding events or results to occur in the future contained in ...